ProMIS Neurosciences (PMN) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and financial position

• Recently completed a large financing round, securing funding through the end of 2027.

• Attracted a strong syndicate of investors in the latest round.

• Actively considering both partnerships and self-funding for future studies, with multiple financing options available.

• Potential to trigger additional CAD 100 million in funding via warrants in Q1 next year.

Lead candidate and clinical development

• Lead asset PMN310 is in a comprehensive phase I-B study (PRECISE-AD) for Alzheimer's, with top-line results expected in Q1 2027.

• Interim blinded data showed a strong safety profile, with zero ARIA-E cases and negligible infusion reactions.

• Biomarker analysis revealed encouraging declines in p-tau217 and MTBR-tau243, suggesting target engagement.

• Study design includes 128+ patients, 12 months of treatment, and a 3:1 randomization to drug vs. placebo.

• If successful, plans to move directly to a single phase III registration study, potentially skipping phase II.

Differentiation and mechanism of action

• PMN310 selectively targets toxic oligomeric amyloid-beta, avoiding monomers and plaque species.

• This approach aims to improve efficacy and safety, reducing ARIA risk compared to existing therapies.

• Proprietary computational methods enable identification of unique conformational epitopes.

• The antibody's specificity avoids the 'sink effect' and off-target binding.